Inventiva (IVA) Revenue (2020 - 2021)
Inventiva's (IVA) quarterly Revenue came in at $78277.6 in Q2 2021, down 3.96% year-on-year from $81508.0 in Q2 2020, and down 12.31% quarter-over-quarter from $89261.5 in Q1 2021.
Inventiva (IVA) Revenue (2020 - 2021) Analysis & Trends
Inventiva's Revenue history runs 2 years deep, the most recent figure standing at $78277.6 for Q2 2021.
- On a quarterly basis, Revenue fell 3.96% year-over-year to $78277.6 in Q2 2021; TTM through Jun 2021 was $345089.9, a N/A change from a year earlier, with the FY2025 full-year figure at $5.2 million, down 66.84% from the prior year.
- Revenue declined to $78277.6 in Q2 2021 per IVA's latest filing, from $89261.5 in the prior quarter.
- Across five years, Revenue topped out at $96042.7 in Q1 2020 and bottomed at $78277.6 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Inventiva | 831.27 Mn | 831.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 78,277.64 |
| Mar 31, 2021 | 89,261.47 |
| Jun 30, 2020 | 81,508.05 |
| Mar 31, 2020 | 96,042.70 |